Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots 

Shots:  The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates  Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights  Denis R. Beckford-Vera, Head of Radiopharmacology…
October 13, 2025

Read more

VIEWPOINTS

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots 

Shots:   Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma     In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape    Leonard also highlights Mino-Lok, Citius’ innovative…
October 6, 2025

Read more

VIEWPOINTS

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots 

Shots:  RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device.  Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, directly targeting the tumor while potentially reducing the toxicities linked to systemic IV chemotherapy.  In…
September 29, 2025

Read more

EVENTS

Post Conference Highlights: Peptides & Complex Generics Symposium 2025

Day 1 Breakdown The #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange. Opening Session Dr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
September 29, 2025

Read more

THOUGHTSPOT

The Rise of Industrial Metaverse: Smarter Pharma Starts at AUTOMA+ 2025 

Digital transformation of the pharmaceutical industry is moving beyond buzzwords to real-world impact. At the Pharmaceutical Automation & Digitalisation Congress AUTOMA+ 2025 (24-25 November, Vösendorf, Austria), pharma leaders, including ZETA GmbH, Takeda and Sapio Sciences, are going to showcase how cutting-edge technologies, from digital twins and predictive analytics to minimal code platforms and AI-driven process…
September 23, 2025

Read more

VIEWPOINTS

Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots 

Shots:  ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders.  Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients.  PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…
September 22, 2025

Read more

VIEWPOINTS

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots:  Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting  Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate  PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025

Read more

Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots
VIEWPOINTS

Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots 

Shots:  Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.  To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
September 15, 2025

Read more

Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots
VIEWPOINTS

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots 

Shots:  The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications.  Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).  Joshua Salsi, the Head of…
September 8, 2025

Read more

Load more